The European Commission (EC) has granted approval of a supply contract with Novavax to purchase more than 200 million COVID-19 vaccines. The deal is an attempt to further diversity the EU’s vaccine strategy after betting heavily on their Pfizer and Moderna vaccine supply. EU regulatory bodies are in the process of reviewing the Novavax vaccine but as part of the contract, the EU will have access to 100 million doses of the shot until 2023. The Novavax deal could see EU states receiving the first set of doses from Q4 of this year. The EU has signed supply deal contracts with six other companies for COVID-19 vaccines, Novavax being their seventh.
Read more here.